List of Figures

Figure 4.1. Overall flowchart of recruitment of subjects in Study & Control groups in both centers

Figure 4.2. Distribution of subjects with respect to gender

Figure 4.3. Distribution of subjects with respect to their medical treatment procedure

Figure 4.4. Distribution of subjects with respect to their risk level

Figure 4.5. Distribution of subjects with respect to number of diseased vessels

Figure 4.6. Mean of PCS &MCS components of Quality of life SF36 at baseline in Study & Control groups

Figure 4.7. Mean of subdomains of SF 36 at baseline in Study & Control groups

Figure 4.8. Mean of LVEF at baseline in Study & Control groups.

Figure 4.9. Mean of Functional capacity at baseline in Study & Control groups

Figure 4.10. Changes in PCS &MCS component of SF36 from baseline to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.11. Changes in mean of PCS component of SF36 from baseline to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.12. Changes in mean of MCS component of SF36 from baseline to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.13. Mean of percentage of changes in subdomains of SF36 in Study & Control groups; Pooled data from both centers

Figure 4.14. Changes in LVEF from baseline to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.15. Changes in functional capacity from baseline to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.16. Changes in BMI from base line to post-intervention in Study & Control groups; Pooled data from both centers

Figure 4.17. Changes in Waist circumference from baseline to post-intervention in Study & Control groups; Pooled data from both centers.
**Figure 4.18.** Mean of percentage of changes from baseline to post-intervention in skinfolds measurements in Study & Control groups; Pooled data from both centers.

**Figure 4.19.** Flowchart of recruitment of subjects in Center I; India

**Figure 4.20.** Gender distribution of subjects in Center I; India

**Figure 4.21.** Distribution of type of medical treatment of subject in center I, India

**Figure 4.22.** Distribution of subjects with respect to Risk stratification in Center I; India

**Figure 4.23.** Distribution of subjects with respect to diseased vessels in Center I; India

**Figure 4.24.** Mean of PCS & MCS components of SF36 at baseline in Study & Control groups in Center I, India

**Figure 4.25.** Mean of Subdomains of SF36 at baseline in Study & Control groups in Center I; India

**Figure 4.26.** Mean of LVEF at baseline in Study & Control groups in Center I; India

**Figure 4.27.** Mean of Functional capacity (MET level) at baseline in Study & Control groups in Center I; India

**Figure 4.28.** Comparison of changes of PCS &MCS components of SF36 from baseline to post-intervention in Study & Control groups in center I; India

**Figure 4.29.** Changes of PCS & MCS components of SF36 from baseline to post-intervention in Study & Control groups in center I; India

**Figure 4.30.** Changes in mean of % of changes from baseline to post-intervention in subdomains of SF36. There was significant difference in all subdomains in both Hospital &Home-based compared with control. The highest improvement was in SF (Social function) and there was a negative change in components of GH (General Health), RE (Role Emotional) in control compared to other study groups.

**Figure 4.31.** Changes in LVEF from baseline to post-intervention in Study & Control groups in center I; India

**Figure 4.32.** Changes in functional capacity (MET) from baseline to post-intervention in Study & Control groups in center I; India
Figure 4.33. Changes in functional capacity from baseline to post-intervention in Study & Control groups in center I; India

Figure 4.34. Flowchart of recruitment of subjects in center II; Iran

Figure 4.35. Gender distribution of subjects in Center II; Iran

Figure 4.36. Distribution of subjects with respect to Medical treatment in center II; Iran

Figure 4.37. Distribution of subjects with respect to risk stratification in center II; Iran

Figure 4.38. Distribution of subjects with respect to number of diseased vessels in center II; Iran

Figure 4.39. Mean of PCS & MCS components of SF36 at baseline in Study & Control groups in center II; Iran

Figure 4.40. Mean of SF36 subdomains at baseline in Study & Control groups in center II; Iran

Figure 4.41. Mean of LVEF at baseline in Study & Control groups in center II; Iran

Figure 4.42. Mean of functional capacity (MET) level at baseline in Study & Control groups in center II; Iran

Figure 4.43. Changes in PCS & MCS components of SF36 from baseline to post-intervention in Study & Control groups in center II; Iran

Figure 4.44. Mean of % of changes in subdomains of SF36 from baseline to post-intervention in Study & Control groups in center II; Iran

Figure 4.45. Changes of LVEF from baseline to post-intervention in Study & Control groups in center II; Iran

Figure 4.46. Changes in Functional capacity (MET) from baseline to post-intervention in Study & Control groups in center II; Iran